Back to listings
Compound & Molecule
Novel KRAS G12C Covalent Inhibitor — Lead Compound
PharmaSynth LabsListed Mar 9, 2026
Description
A first-in-class covalent small molecule inhibitor selectively targeting KRAS G12C mutation in non-small cell lung cancer. IC50 of 0.8 nM in biochemical assay, EC50 of 12 nM in NCI-H358 cell line. Excellent oral bioavailability (78% in rat PK studies) and CNS penetration. IND-enabling studies completed, ready for Phase I.
Tags
KRASoncologyNSCLCcovalent inhibitorIND-ready
Technical Details
- CAS Number
- 2189684-45-3
- Molecular Weight
- 560.67 g/mol
Asking Price
$6,500,000
About the Seller
Prof. James O'Brien
PharmaSynth Labs
Drug discovery expert specializing in oncology and rare diseases.